AMENDMENT AND RESTATEMENT OF THE PLUS THERAPEUTICS, INC. SERIES A COMMON STOCK PURCHASE WARRANT

AMENDMENT AND RESTATEMENT

OF THE

PLUS THERAPEUTICS, INC.

SERIES A COMMON STOCK PURCHASE WARRANT

 

This Amendment and Restatement (this “Amendment”), dated as of August 9, 2024 (the “Effective Date”), is made and entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Series A Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $[•] per share, originally issued by the Company to the Holder on May 9, 2024 (the “Warrant”).

 

WHEREAS, the Holder is the holder of the Warrant; and

 

WHEREAS, the Holder and the Company have agreed to amend and restate the Warrant pursuant to the provisions of Section 2(a), Section 2(d)(ii) and deletion of Section 2(f) of the Warrant.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

 

 

 

c. Continuation of the Warrant. Except as expressly modified by this Amendment, the Warrant shall continue to be and remain in full force and effect in accordance with its terms. Any future reference to the Warrant shall be deemed to be a reference to the Warrant as modified by this Amendment.

 

 

(signature pages follow)

---

IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above.

 

 

PLUS THERAPEUTICS, INC.

 

By:________________________________ Name: ▇▇▇▇▇▇ ▇▇▇▇

Title: Chief Financial Officer

---

IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above.

 

 

Holder Name

 

By:________________________________ Name:

Title:

 

 

---

Exhibit A

 

Form of Series A Common Stock Purchase Warrant, as Amended and Restated

 

(See attached)

---